Wall Street analysts expect Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) to announce ($0.33) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Threshold Pharmaceuticals’ earnings. Threshold Pharmaceuticals reported earnings of ($0.88) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 62.5%. The company is expected to issue its next quarterly earnings report on Monday, November 6th.

On average, analysts expect that Threshold Pharmaceuticals will report full-year earnings of ($1.03) per share for the current financial year, with EPS estimates ranging from ($1.32) to ($0.74). For the next financial year, analysts forecast that the business will post earnings of ($1.44) per share, with EPS estimates ranging from ($2.09) to ($0.78). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Threshold Pharmaceuticals.

Threshold Pharmaceuticals (NASDAQ:MTEM) last announced its earnings results on Monday, July 31st. The biotechnology company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.99. The business had revenue of $3 million during the quarter.

Several brokerages have recently commented on MTEM. ValuEngine upgraded Threshold Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 3rd. Stifel Nicolaus restated a “hold” rating and issued a $0.40 price objective on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. Finally, Ladenburg Thalmann Financial Services began coverage on Threshold Pharmaceuticals in a research report on Thursday, August 3rd. They issued a “buy” rating and a $10.00 price objective on the stock.

Shares of Threshold Pharmaceuticals (NASDAQ:MTEM) traded up 2.9060% during trading on Wednesday, reaching $5.1453. The company’s stock had a trading volume of 49,409 shares. The company’s market cap is $138.31 million. The company has a 50 day moving average of $5.33 and a 200 day moving average of $5.71. Threshold Pharmaceuticals has a 12-month low of $3.85 and a 12-month high of $16.28.

In other news, Director Jeffrey W. Bird bought 510,703 shares of Threshold Pharmaceuticals stock in a transaction dated Thursday, June 1st. The shares were purchased at an average cost of $0.57 per share, with a total value of $291,100.71. Following the completion of the acquisition, the director now owns 919 shares of the company’s stock, valued at approximately $523.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 12.97% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Brokerages Anticipate Threshold Pharmaceuticals, Inc. (MTEM) Will Announce Earnings of -$0.33 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/08/16/brokerages-anticipate-threshold-pharmaceuticals-inc-mtem-will-announce-earnings-of-0-33-per-share.html.

Threshold Pharmaceuticals Company Profile

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Get a free copy of the Zacks research report on Threshold Pharmaceuticals (MTEM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.